MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of anticancer therapies. The company’s products include Zalmoxis (TK), a cell based therapy product, which is in Phase III clinical trial in acute leukemia that is used for the treatment of hematological malignancies. Its products also comprise NGR-hTNF, a therapeutic agent for solid tumors, which is in Phase II trials in seven types of solid tumors, such as monotherapy in colorectal cancer, hepatocellular carcinoma, and mesothelioma; and in combination with standard chemotherapeutic agents in small-cell lung cancer, non-small cell lung cancer, ovarian cancer, and soft-tissue sarcoma, as well as in Phase III trials in mesothelioma patients. In addition, the company’s preclinical development products include CAR-CD44v6, an immuno-gene therapy project for the treatment of various hematological malignancies and epithelial tumors. Further, it conducts cell and gene therapy projects in collaboration with third parties, such as the cGMP production of clinical-grade viral vectors; and manufacturing of patient-specific genetically engineered cells. The company was founded in 1996 and is headquartered in Milan, Italy.
molecular medicine spa
Via Olgettina, 58
Milan, MI 20132
Phone: 39 02 21 27 71
Fax: 39 02 21 27 73 25www.molmed.com
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for MLM.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact MOLECULAR MEDICINE SPA, please visit www.molmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.